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Abstract
Heart failure is a life-threatening disease, and its solution should be seen as a global health 
priority. Heart failure is indeed a complex disease and has until now been the leading 
cause of morbidity and mortality in developing and developed countries. Standardized 
medical therapy was successful in the early stages of heart failure. The advanced stages 
of heart failure require frequent hospitalization because of the presence of severe heart 
failure and/or associated comorbid conditions that require the strict implementation of 
an adequately individualized multidisciplinary approach and quality measures. Even 
after the development of heart failure, premature deaths can be prevented if they are 
taught to recognize symptoms and seek immediate medical attention. Public awareness 
campaigns on these messages have a great potential for improving outcomes for patients 
with heart failure and, ultimately, for saving lives. It is also quite possible that the preven-
tion of cardiovascular diseases (CVD) in the adult population of the current generation 
to some extent is only a delay of events or a reduction in mortality from the case, rather 
than complete prevention. Preventing premature death from cardiovascular disease and 
years of life adjusted for disability is large but may be due to an increase in the prevalence 
of cardiovascular disease in the elderly and in very old cases with an epidemic of cardio-
vascular diseases in the terminal stage, such as chronic heart failure, renal insufficiency, 
and vascular dementia with all its consequences in terms of greater need for care than for 
treatment and increased costs of sanitation protection. Continuing research is needed if 
we want to solve the unmet need for care for patients with heart failure. New methods 
of treatment are needed for patients with types of heart failure, for which modern treat-
ments ease the symptoms, but do not affect the disease. In the economically developing 
world, more accessible methods of treatment are desperately needed. International col-
laborative research on the causes and methods of treating heart failure around the world 
can benefit tens of millions of people. Compliance with the recommendations of clinical 
practice is also associated with improved results for patients with heart failure. However, 
there are significant differences in how closely the doctors follow the recommendations. 
In order to promote equitable care, improvements should be promoted through the use 
of indicators and incentives for hospitals that are appropriate to local conditions. To this 
end, the policy should facilitate the research needed to create an evidence base for perfor-
mance indicators that reflect improved outcomes for patients.
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1. Introduction
Cardiovascular disease (CVD) remains the leading cause of death, premature mortality, 
and disability worldwide. The mortality rate from CVD has been declining since the early 
1990s as a result of significant changes in lifestyle and improved health care. This growing 
prevalence is due to improved survival of people with myocardial infarction and patients 
with heart failure and a high burden of heart risk factors for people such as hypertension, 
obesity, diabetes, and smoking. While physical activity and regular exercise are emphasized 
for the development of general cardiovascular health, modern guidelines for heart failure 
inadequately emphasized the importance and recommendations for physical activity as a 
means of preventing a condition [1–3].
Nevertheless, there are certain regions with significantly higher total and mortality from car-
diovascular diseases, despite relatively good access to medical care and invasive cardiology 
procedures. Previous reports conducted among residents of these regions showed adverse 
lifestyles with a very low prevalence of people who follow current recommendations for the 
prevention of cardiovascular diseases. This poor adherence to recommended recommenda-
tions may be a function of a lack of awareness of the methods of preventing CVD. Several 
studies have indicated that improving awareness of the risk factors for cardiovascular disease 
and prevention can be a prerequisite for adopting of a healthy lifestyle [2–5].
To determine the most effective ways to solve the problem of heart failure in different parts of 
the world, an international approach is needed, as well as the inclusion of necessary measures 
in everyday practice. Political initiatives at the local, national, and international levels can 
reduce mortality due to heart failure and improve the quality of life of patients.
2. The global burden of heart failure
In recent years, the survival rates of patients with heart failure have improved in many parts 
of the world, in parallel with the introduction of modern evidence-based methods and patient 
management systems. Nevertheless, about 2–17% of those admitted to the hospital with heart 
failure die in the hospital. Survival rates are better for those who are treated in outpatient 
clinics, which usually have less pronounced symptoms than those who are treated in the hos-
pital. However, even the newest therapies can only alleviate the symptoms in many patients 
without slowing the progression of their disease or prolonging life. This is due to the fact that 
heart failure can arise due to a number of different underlying problems with the structure or 
function of the heart, some of which are more difficult to treat than others [3, 4].
HF may seriously damage developing countries by creating loss of productivity of cardiac 
patients. It often severely limits a person’s ability to work. Loss of productivity hurts not only 
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the individual but affects the family’s income and the country itself by extension. Also, the 
weakened cardiac patients often need caregivers; consequently, a caregiver often is a family 
member, and he or she has to stop working in order to nurse a cardiac patient at home. To 
treat HF and maintain good health in cardiac patients, it is necessary to prescribe several 
medicines that can be difficult to afford for some people [5–7].
Unfortunately, globalization creates unforeseen problems for most low- and middle-income 
countries. Adaptation of the western way of life and malnutrition of developed countries are 
spreading around the world. Limited financial resources and the weak structure of health 
systems in developing countries pose a barrier to managing the impending global epidemic of 
chronic diseases. The need to adapt evidence-based treatment plans and model approaches to 
public health from successful experiences of other countries should become urgent priorities 
for low- and middle-income countries [8].
Infections remain a common cause of heart failure in many parts of the world and can affect 
any age. Heart failure is not a disease of the elderly in sub-Saharan Africa, where half of the 
patients hospitalized with this disease are 55 years or younger. Patients in the Asia-Pacific 
region are also usually younger than in the western regions. Rheumatic fever due to prevent-
able bacterial infections is an important cause of heart failure in Africa, Asia, Australia, and 
Latin America. HIV infection is also a major source of cardiovascular disease worldwide. In 
areas of Latin America where Chagas disease is prevalent, almost half of all cases of heart 
failure are the direct result of this preventable parasitic infection [9–11].
Heart failure is a widely researched disease because of its burden. There are many studies in 
which the incidence of heart failure is positively associated with several risk factors. The very 
first study that addressed the etiology of this disease was a cohort study that followed people 
for 20 years, a study of the heart of Framingham in the 1970s. According to the Framingham 
Heart Study, heart failure had several major risk factors. It was found that the highest risk 
factor for heart failure among the population is hypertension, which accounts for 39% of heart 
failure in men and 59% in women. The second most significant risk factor was myocardial 
infarction, which accounts for 34% of heart failure in men and 13% in women. Other impor-
tant risk factors were diabetes mellitus, left ventricular hypertrophy, and heart valve disease. 
This was the first scientific evidence of heart failure associated with behavioral factors [12–14].
It has been proven that reducing risk factors will eventually reduce the likelihood of devel-
oping heart failure. Most cases of heart failure (90%) are explained by risk factors, such as 
diabetes, obesity, smoking, blood pressure, and high cholesterol. By reducing BMI, stopping 
smoking, keeping low cholesterol and blood pressure, and avoiding the other mentioned risk 
factors, people can potentially be protected from heart failure, cardiovascular diseases, and 
other chronic diseases. Knowledge of risk factors is very important for the prevention of HF, 
but they can also be used to combat heart failure and cardiovascular diseases [11, 13–15].
Heart failure significantly affects the quality of life of patients. Fear, anxiety, and depres-
sion are common, and work, travel, and everyday social and leisure activities are difficult for 
people with shortness of breath and extreme fatigue. Emotional, physical, and financial costs 
are also high for those who care for family members with heart failure. Heart failure leads to 
a large number of deaths and a widespread disease and requires huge economic and social 
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costs, and the problem worsens. It is time for coordinated awareness programs about heart 
failure and strategic and policy initiatives to improve patient care.
3. Preventing heart failure in high-risk groups
Prevention of heart failure is of paramount importance. After an establishment the deterio-
ration of a status of the heart can be often treated, but as a rule, it is impossible to cancel. 
Policymakers should emphasize the need for health professionals in all clinical disciplines to 
identify patients with diseases that increase the risk of heart failure and prescribe preventive 
drugs. Ensuring access to preventive drugs should be provided to those who are at greatest 
risk for developing heart failure, regardless of age, sex, or income. Policymakers should also 
give priority to the elimination of certain infectious diseases in some parts of the world where 
they continue to cause heart failure [4, 8, 10].
Risk factors for heart failure vary from lifestyle factors to concomitant diseases, medications, 
laboratory, and visual characteristics for new biomarkers and genomic markers. The risk of 
heart failure increases with age, and the male sex is associated with a higher risk. Higher 
physical activity, increased salt intake, and lower socioeconomic status were associated with 
increased risk. Hypertension, diabetes, obesity, and coronary disease all increase the risk. 
More than half of patients hospitalized with heart failure, regardless of the ejection fraction, 
have coronary artery disease. Hypertension and coronary artery disease are the most com-
mon and most powerful risk factors, which bring an increased risk of two to three times. 
Valvular heart disease increases the risk due to hemodynamic changes.
Obesity, due to a variety of mechanisms, predisposes to heart failure. The excessive use of 
alcohol increases blood pressure and is a direct myocardial toxin; however, light consump-
tion is moderately associated with risk, especially in men. Smoking contributes to several 
cardiovascular risk factors associated with heart failure. Dyslipidemia and renal dysfunction 
predispose to heart failure. Other comorbidities that increase the risk include anemia, sleep 
breathing disorder, increased heart rate, lung dysfunction, and microalbuminuria. The levels 
of homocysteine and natriuretic peptide are associated with an increased risk. Serum resis-
tance, lipoproteins associated with phospholipase A2, and myeloperoxidase are also associ-
ated with an increased risk [9–12].
Most patients are fragile and elderly with concomitant diseases (e.g., concomitant respiratory 
diseases and renal dysfunction) that can limit and/or complicate treatment. Although formal 
classification systems have been developed, the most practical indicator of an increased risk of 
premature morbidity and mortality or reentering the hospital is the presence of two or more 
of the following:
• Age ≥ 65 years
• NYHA class III or class IV symptoms
• Charlson Index of Comorbidity Score of 2 or more
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• Left ventricular ejection fraction (LVEF) ≤ 30%
• Living alone or remote from specialist cardiac services
• Depression
• Language barrier (e.g., non-English speaking)
• Lower socioeconomic status (due to poorer compliance, reduced understanding of reasons 
for medicines, fewer visits to medical practitioners, high-salt diet in “take-away foods,” 
reduced ability to afford medicines, higher rates of cigarette smoking, etc.)
• Significant renal dysfunction (glomerular filtration rate < 60 mL/min/1.73 m)
Several chemotherapeutic agents, for example, doxorubicin, cyclophosphamide, trastuzumab, 
and 5-fluorouracil, are associated with heart failure. Inhibitors of cyclooxygenase-2 may 
increase the risk of myocardial infarction. Thiazolidinediones were associated with edema 
and heart failure. Several cardiac anatomical and physiological measures are associated with 
a higher risk, including enlargement of the chamber with an increase in terminal diastolic or 
terminal systolic dimensions, an increase in left ventricular mass, worsening diastolic filling 
of the left ventricle, an increase in the left atrium, and asymptomatic systolic dysfunction. 
There is growing interest in genomic predictors of heart failure.
While patients at high risk benefit greatly from proper and consistent treatment, unfortu-
nately, they often undergo suboptimal management. Their inability to tolerate even minor 
fluctuations in cardiac and renal function makes them vulnerable to frequent and recurring 
episodes of acute heart failure.
It is now recognized that up to two-thirds of hospitalizations associated with CHF can be 
prevented. The following variables are most often associated with poor health outcomes, 
especially in high-risk patients:
• Inadequate/inappropriate medical or surgical treatment
• Adverse effects of prescribed therapy
• Inadequate knowledge of the underlying illness and prescribed therapy
• Inadequate response to, or recognition of, acute episodes of clinical deterioration
• Nonadherence to prescribed pharmacological treatment
• Lack of motivation/inability to adhere to a non-pharmacological therapy
• Problems with caregivers or extended care facilities
• Inadequate social support
This is especially important for groups at high risk of developing this condition. Many people 
have diseases that put them at risk of heart failure. Health-care professionals who treat such 
patients should adopt a broad approach that includes encouraging positive lifestyle changes 
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that reduce the risk of heart failure and prescribe preventive therapy as needed. Medications 
that control blood pressure, heart rate, and cholesterol levels are effective in preventing heart 
failure in a large number of people who have conditions such as high blood pressure, coronary 
heart disease, kidney disease, and diabetes. Pacemakers and the replacement of heart valves 
can also prevent heart failure in a small number of people who have a particular heart rate or 
valve disorders. The range of diseases that predispose patients to heart failure is extremely 
wide. Health-care professionals in all clinical disciplines should receive education to identify 
patients with diseases that increase the risk of heart failure and prescribe preventive medica-
tions. This ensures that as many people as possible get access to therapy [5, 7, 8].
Patients receiving long-term preventive therapy should be evaluated regularly at the expense 
of health-care providers. In addition, patients with chronic diseases, such as coronary artery 
disease or Chagas disease, should periodically evaluate and monitor heart changes. Patients 
with breast cancer are another group that will benefit from such monitoring. Several existing 
and new methods of treating cancer are toxic to the heart, and it is important for health profes-
sionals to be aware of the need to evaluate and manage the risks involved.
Bacterial infections that cause heart disease are largely eliminated in economically developed 
countries due to the use of antibiotics. In other regions, bacteria and tropical parasites cause 
a significant proportion of heart failure, many of which can be prevented by appropriate 
treatment methods. Therefore, the potential benefits of policy initiatives aimed at eliminating 
infectious diseases extend to preventing heart failure in many parts of the world. In particular, 
to continue global efforts, it is necessary to eradicate Chagas disease, based on the progress 
made in Latin America over the past two decades [1, 2].
Preventive treatment could be started earlier, identifying people with early signs of abnormal 
cardiac muscle remodeling. Unfortunately, large-scale screening programs, such as those that 
allowed earlier treatment of bowel cancer, cervical cancer, and breast cancer, are unfortu-
nately not possible, because there is no simple diagnostic test for heart failure. Early changes 
in the structure or function of the heart can be detected using medical imaging technology; 
however, it is inadvisable to perform these complex procedures in a large number of people 
with diseases that lead to heart failure and, of course, not for the general population. In the 
future, extended genetic tests and statistical modeling of risk groups that take into account 
the myriad potential causes of heart failure may be available, and this can allow individuals 
to be identified for in-depth screening.
Targeting preventive drugs to people with the highest risk of heart failure can increase profit-
ability, allowing more people to take advantage. Further research in these areas continues and 
should continue to be supported by public and private funds. In addition, information programs 
should be directed at everyone who has medical conditions that predispose to heart failure. 
They should include education about the symptoms of heart failure and the benefits of positive 
lifestyle changes. The same messages are important for public information programs [3–6].
Preventing heart failure in the elderly is becoming a more urgent health priority, as the age 
of the population. Heart failure is the most common cause of hospitalization in people older 
than 65 years in economically developed regions. Elderly patients hospitalized with heart 
failure mostly are women. Although a number of studies of patients with heart failure have 
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shown that survival rates are better in women than in men, recent studies have shown that 
long-term prospects for women are not as good as previously thought. Therefore, initiatives 
aimed at improving the prevention of heart failure should include strategies to reach older 
people, especially older women [14–16].
In economically developed countries, heart failure is more common and most likely the cause 
of death in people with low socioeconomic status than the rest of the population. This is still 
the case after adjusting for age differences, the use of drugs, and the proportion of people 
with other cardiac diseases. The view was expressed that the role of housing can be played 
by housing stability, social support, substance abuse, language skills, and distance to the 
hospital.
Several studies have reported a reduction in the risk of heart failure with a healthy lifestyle. 
It has been shown that healthy weight, avoidance of smoking, exercise, and healthy eating 
reduce the risk factors for heart failure, including ischemic disease, diabetes, and hyperten-
sion. Recently, researchers in the health research of doctors reported that habits of a healthy 
lifestyle, that is, normal body weight, rather than smoking, regular exercise, moderate alcohol 
consumption, consumption of breakfast cereals, and consumption of fruits and vegetables, 
were associated with a lower risk of heart disease with the most high risk of 21.3% in men 
who do not observe any of these habits and the lowest risk of 10.1% in men who adhere to 4 
or more of them.
4. Healthy lifestyle, behavior, and socioeconomic issues
Although many heart failure risk factors have been described, determining their role in pre-
dicting a future event is still difficult. Despite a strong etiological relationship to the disease, 
the risk factor may be limited in its prognostic role. Although individual risk factors for heart 
failure, such as hypertension, are well described, how do we clearly identify individual risk in 
patients with different combinations of risk factors? For coronary events, schemes for predict-
ing multiple risks have been developed, for example, the Framingham risk score. However, 
heart failure syndrome is a spectrum from ischemic to nonischemic etiology and from normal 
to depressed ejection fraction. Older patients may develop heart failure due to age-related 
cardiovascular changes in the absence of traditional risk factors. Thus, high-risk subjects can-
not be detected using coronary risk regimes [15].
Several unique problems make the assessment of the risk of heart failure difficult. First, heart 
failure is a clinical diagnosis, and this leads to a variety of opinions and diagnostic uncertain-
ties in a number of cases. The most common clinical criteria used to diagnose heart failure 
are the Framingham criteria, which require at least two basic or one basic and two lower cri-
teria. The main criteria include paroxysmal nocturnal dyspnea, a dilated vein in the throat, 
rales, radiographic cardiomegaly, acute pulmonary edema, gallop S3, increased venous pres-
sure > 16 cm H2O, circulation time ≥ 25 seconds, hepatojugular reflux or pulmonary edema, or 
visceral cluster or cardiomegaly at the autopsy. Minor criteria included bilateral ankle edema, 
night cough, shortness of breath with normal tension, hepatomegaly, pleural effusion, a 
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decrease in vital capacity by one-third of the maximum, and heart rate ≥ 120 beats per minute. 
Researchers from the cardiovascular study have developed alternative criteria that included 
the use of drugs and imaging techniques. When both sets of criteria were compared, only half 
of the patients were considered to have heart failure by both criteria, while the other half were 
labeled either one or the other, but not both. A similar discrepancy was shown between diag-
noses of administrative categories compared to a detailed overview of the diagram [2, 13–16].
Social changes can affect the CVD epidemic in different ways. It may be influenced by global-
ization, migration, socioeconomic changes, and unemployment. Over the years, differences in 
the incidence of CVD among countries, regions, and areas have increased; these inequalities 
can be explained by the components of human behavior, such as diet, exercise, smoking, 
and work-related functions, as well as overcrowding, unemployment, and other deprivation 
indicators. The expected life expectancy is constantly increasing with income.
5. Smoking of tobacco
Smoking is a strong predictor of heart failure in men and women; 45% and 88% have an 
increased risk. The harmful effect of tobacco, apparently, does not depend on the form of use. 
An increased risk of cardiovascular disease is reported when tobacco is used by non-smokers. 
There is no “safe” level of smoking; a single cigarette can strengthen the left ventricle, and 
only one to four cigarettes a day double the risk of myocardial infarction. Mechanisms leading 
to heart failure in smokers include (i) indirect effects, that is, causing or exacerbating associ-
ated diseases associated with heart failure, and (ii) direct exposure to the myocardium.
Tobacco smoking remains one of the most important preventable causes of premature mortal-
ity, and quitting is the most cost-effective strategy for the prevention of cardiovascular disease. 
Improvements have been made with regard to tobacco smoking, in some countries more than 
in others, with large differences in accordance with the socioeconomic class. Governmental 
constraints and rules were successful; high taxes on tobacco products are the most effective 
policy measure to reduce smoking among young people. However, this needs to be comple-
mented by continuing campaigns in the field of health education, especially those targeting 
young people and other subgroups of society. There must be restrictions on advertising, pro-
motion, and sponsorship by the industry [12, 16].
All smokers should be advised to quit. Patients should be referred to formal programs to 
discontinue therapy, and pharmacological therapy should be offered to increase success. 
Current recommended strategies include the following: (a) Medicines. Several drugs are 
available for tobacco dependence. Seven first-line drugs significantly increase long-term rates 
of abstinence from smoking, including bupropion SR, nicotinic gum or inhaler or cake or 
nasal spray, or patch and varenicline. (b) Counseling and psychosocial support. Individual, 
group, and telephone practical consultations and social support are effective, and their effec-
tiveness increases with the intensity of treatment. (c) Combination. However, the combination 
of counseling and medication is more effective than one, so clinicians should encourage all 
people who attempt to stop using both counseling and medication.
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Smokers who want to quit smoking should get professional help if needed. Short interven-
tions with recommendations for cessation of smoking, together with pharmacological support 
and follow-up visits, are effective and safe, but not enough, even for smokers with established 
ischemic heart disease. If the smoker is ready to stop, a termination plan should be prepared, 
including the release date, information for friends and families asking for support, and remov-
ing all tobacco and smoking-related items from the immediate environment and, finally, ideally 
within a month and every month after that for 4 months. On a subsequent visit, a person should 
be congratulated if he/she has stopped smoking. In case of relapse, a more intensive approach 
should be considered, for example, referral of a specialist or center for cessation of smoking. 
Avoidance of secondhand smoke is another important recommendation for CVD prevention.
If the recommendations, stimulation, and motivation are likely to be insufficient, drug ther-
apy should be considered at an early stage, including nicotine replacement therapy (NRT), 
bupropion, or varenicline. Pharmacotherapy for smoking cessation can double or triple throw 
rates, and a combination of pharmacotherapy and counseling improves throw rates.
The success of cessation of smoking with varenicline is higher than with bupropion; var-
enicline doubles the chances of stopping smoking compared to placebo. Varenicline reduces 
cravings for cigarettes and withdrawal symptoms; it should be run 1 to 2 weeks before the 
release date. Hypersensitivity is the only contraindication. Nausea is the most common side 
effect, especially at the beginning of therapy and if taken with food. In some cases, a dose 
titration may be required.
Electronic cigarettes, or e-cigarettes, can deliver high concentrations of nicotine as a vapor 
and have been recommended as a measure to help stop smoking conventional cigarettes. The 
results of studies of the cardiovascular effect of electronic cigarettes are inconsistent, but in 
some cases, an increased risk is documented.
6. Dietary habits
As for the dietary habits of the population, the changes occurred in different areas. For 
example, consumption of salt and saturated fats has been reduced in most societies. The food 
industry has reduced the presence of trans-fatty acids in different foods. This was promoted 
by regulatory initiatives in some communities. Nevertheless, the potential for preventing 
cardiovascular disease through dietary adaptations is still poorly implemented. Compliance 
with a balanced diet is usually limited. Control of high blood pressure, dyslipidemia, and 
dysglycemia can be significantly improved due to lifestyle changes. Achieving better adher-
ence to dietary recommendations requires an understanding of the determinants of poor 
compliance. At the population level, structural measures, such as product information and 
user-friendly food labeling, can improve health-friendly options. Energy-intensive products 
with nutrient deficiencies are usually highly available and inexpensive; marketing of such 
products may be limited and taxed.
In the diet “Dietary Approaches to Stopping Hypertension” (DASH), people are encouraged 
to consume more (i) fruits and vegetables; (ii) grains and cereals; (iii) lean meat, fish, and 
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poultry; (iv) low-fat or low-fat dairy products; and (v) nuts, seeds, and pulses and reduce 
consumption of red meat, fat, and sugar while maintaining low-sodium intake. Initially it 
was elevated for hypertension; however, recent data confirm a reduction in the risk of heart 
failure with an observed decrease of 37% in women who adhere to the DASH diet. The DASH 
diet can help prevent heart failure by lowering blood pressure and coronary heart disease. 
Daily consumption of whole grain breakfast cereals was associated with a 30% reduction in 
heart failure, egg consumption more than twice a day was associated with an increase of 64%, 
fish consumption was associated with a 20–31% lower heart failure rate depending on con-
sumption, and consumption of 100 mmol or more of sodium was associated with a 26% rate; 
only the consumption of nuts was not associated with heart failure. Whole grains can protect 
against the risk of heart failure as a result of exposure to weight, hypertension, myocardial 
infarction, and diabetes mellitus.
Fish consumption has a beneficial effect on the risk of heart failure with about 20% less risk 
associated with consumption one to two times a week and about 30% less risk when con-
sumed ≥3 times a week, compared with consumption less than one time per week/month. 
The estimated consumption of marine n-3 fatty acids was associated with a 37% reduction in 
the risk of heart failure in the highest quintile of consumption compared to the lowest. Short-
term tests of fish oil supplementation of 3–5 g per day can reduce the risk, while dietary doses 
of about 0.5 g per day can lead to more modest effects, which over time can reduce the risk of 
heart failure. It has been reported that the consumption of fried fish or baked fish is inversely 
related to systolic blood pressure, C-reactive protein level, and carotid intimal medial thick-
ness, while consumption of fried fish is positively associated with them, indicating that the 
type of preparation can influence the effects.
At the clinical level, general practitioners have the opportunity to provide advice on a diet 
for treating risk factors for coronary diseases. However, obstacles related to time constraints, 
knowledge, and perceived effectiveness were reported. The degree to which doctors are familiar 
with a healthy dietary pattern (i.e., DASH, the Mediterranean diet) and with the translation of 
this information into practical recommendations may be limited. A multidisciplinary approach, 
including dieticians and nutritionists, can help but needs to improve coverage of reimbursement.
At the individual level, new strategies can help improve patient self-control and lead to a 
sustained behavior change. Many applications and devices are available that provide data 
that can be useful for lifestyle changes and patient self-care.
7. Physical activity
Physical inactivity is an important risk factor for cardiovascular disease, including heart failure. 
Regular physical activity has important and broad benefits, such as reducing the risk of cardiovas-
cular disease, hypertension, and diabetes. Physical activity is a key to good health and an impor-
tant component of weight loss and weight maintenance, improving the profile of lipoproteins and 
reducing the risk of hypertension, diabetes, and coronary artery disease. These favorable effects 
on the profile of cardiovascular risks, in turn, reduce the likelihood of heart failure [14–16].
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Promotion of physical exercises is a crucial and central issue in all strategies for the preven-
tion of cardiovascular diseases. At the individual level, physical activity should be recom-
mended at different times; he must become part of ordinary life from childhood. Children and 
adolescents should be encouraged to spend from 30 to 45 minutes of exercise at school or in 
their free time every day. This should be maintained as long as possible, through adolescence 
to adulthood.
Physical activity can also reduce left ventricular hypertrophy and improve endothelial func-
tion. Chronic physical activity reduces the production of cytokines by fat tissue, skeletal 
muscles, and endothelial and blood mononuclear cells and regulates antioxidant enzymes. 
These modifying effects on risk factors for heart failure or the intermediate pathways leading 
to heart failure can reduce heart failure. Integration of physical activity into everyday life of 
the population proved to be a difficult task.
Healthy adults in all age groups are encouraged to choose pleasant physical exercises that fit 
into everyday life on most days of the week. It is recommended to perform at least 150 minutes 
per week of moderate aerobic physical activity (30 minutes for 5 days a week) or 75 minutes 
per week of intense aerobic physical activity (15 minutes for 5 days a week) or a combination 
thereof. At the individual level, the purpose of the exercise should be more personalized. 
Therefore, a brief history of the individual’s physical level is needed (how many minutes per 
day is spent on average with activity at moderate or strong intensity).
Currently, the recommendations of the American College of Sports Medicine and the 
American Heart Association for regular physical activity in healthy adults 18–65 years include 
the following: (a) Aerobic activity. Aerobic physical activity with moderate intensity for at 
least 30 minutes for 5 days a week or intense aerobic activity for a minimum of 20 minutes 
for 3 days a week. (b) Strengthening of muscles. It is recommended that 8–10 exercises are 
performed for 2 or several days without Monday to a week using the main muscle groups. 
To maximize the development of strength, you should use resistance (weight), which allows 
you to perform 8–12 repetitions of each exercise, which leads to strong-willed fatigue. (c) Dose 
of activity. Activity of intensive intensity can have a greater benefit than physical activity of 
medium intensity.
Walks have been reported as useful for primary prevention; this should be done by individu-
als who do not adhere to current recommendations.
Based on this and taking into account the individual choice, it is possible to give advice on 
the most appropriate activities, on how to move forward, about what goals should be set to 
achieve and maintain health benefits from active lifestyles. It is necessary to identify barriers 
to achieving a more active lifestyle, perceived by the individual, and to explore ways of over-
coming them. For people at work, it is recommended to recommend an active trip, as well as 
active breaks from long periods of sitting. In people who are not able to perform a minimum, 
or in inactive subjects who are just beginning to engage in any activity, even the lowest recom-
mended level should be recommended. It should be emphasized that any increase in activity 
will be associated with a beneficial health impact, even before the learning effect becomes 
apparent, and that it is normal for gradual work for any given purpose.
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7.1. Overweight and obesity
There are several plausible mechanisms for the association of obesity and an increased risk 
of heart failure. Indirect but well-known and documented mechanism is the effect of obesity 
in heart failure with the help of other risk factors. The increase in BMI is a risk factor for the 
development of hypertension, diabetes mellitus, and dyslipidemia, all of which increase the 
risk of myocardial infarction, which is an important precursor of heart failure. In addition, 
hypertension and diabetes mellitus independently increase the risk of HF occurrence. It has 
also been shown that increased BMI is associated with altered left ventricular remodeling, 
possibly due to increased hemodynamic loading, neurohormonal activation, and increased 
oxidative stress. Studies have shown that obesity can have a direct effect on the myocardium, 
demonstrating a loss of cardiac function through cardiac steatosis and lipoapoptosis.
The body mass index is associated with heart failure in a positive and linear way in both 
sexes. Although the body mass index in the obesity area (≥30 kg/m2) is clearly associated 
with an increased risk of heart failure, there are disputes regarding the body mass index in 
the overweight range (25–29.9 kg/m2). However, recent data confirm that overweight is also 
associated with heart failure. Abdominal obesity may be a stronger predictor of heart failure 
than complete obesity, even in the absence of coronary heart disease. Several mechanisms 
have been proposed that increase the body mass index, the risk of heart failure, including 
(a) changes in the cardiac load, (b) changes in cardiac structure and function, (c) activation 
of neurohumoral and inflammatory pathways, (d) promotion of atherogenic conditions, (e) a 
predisposition to breathing with sleep disorders, and (f) a chronic kidney disease.
Although elevated BMI is well known as a risk factor for heart failure, this study showed that 
an elevated BMI is not a risk factor for increasing mortality but rather is associated with a 
trend toward improved survival. This counterintuitive epidemiological link between survival 
outcomes and traditional risk factors is called reverse epidemiology or “paradoxical obesity,” 
and it is now well documented in numerous studies and in the literature on heart failure.
The exact mechanisms underlying the paradox of obesity have not been clearly defined. There 
are several theories. A common explanation for the increase in survival in obese patients with 
heart failure is that additional fatty tissue provides greater reserves against catabolic changes 
associated with the disease process that can lead to cardiac cachexia. Cardiac cachexia is a 
syndrome that includes progressive weight loss and changes in the body composition, which 
carries a destructive prognosis for heart failure, as well as in other painful conditions.
The basic approach to risk reduction for obese patients should include weight control and 
physical activity, as well as control of related risk factors such as hypertension, diabetes, 
sleep disorders, and metabolic syndrome components. Changes in the myocardium with 
nonsurgical or surgical weight loss are possible, and a slight weight loss is effective; weight 
loss of 10% reduces systolic dysfunction, and a weight loss of 8–10 kg leads to a significant 
decrease in the size of the left ventricle and the mass index and improves diastolic function. 
Significant weight loss reduces the thickness and volume of the wall of the left ventricle, 
filling pressure, improves diastolic parameters, and improves systolic function of the left 
ventricle. The role of metabolic and neurohumoral modification may take precedence over 
hemodynamic effects, since left ventricular mass or functional improvement occurs indepen-
dently of load changes.
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7.2. Alcohol consumption
Although epidemiological data constantly demonstrate the harmful effects on health associ-
ated with alcohol use, current literature cites some evidence of reducing the risk of heart fail-
ure with mild and moderate alcohol consumption. However, in order to fully understand the 
relationship between mild to moderate alcohol consumption and heart failure, several gaps 
need to be filled, especially the role of alcohol samples, beverage types, and genetic varia-
tions affecting alcohol metabolism and the effect of light on moderate drinking in predicting 
mortality and concomitant morbidity among people with heart failure. In the absence of large 
randomized studies of moderate alcohol consumption and heart failure, residual mixing or 
immeasurable confusion cannot be ruled out as possible explanations of the observed rela-
tionships. Thus, for patients who do not consume alcohol, it would be premature to recom-
mend mild to moderate alcohol consumption as a means to reduce the risk of HF, given the 
possible risk of abuse and the resulting consequences.
Excessive consumption of alcohol is associated with alcoholic cardiomyopathy. Interestingly, 
other data are consistent with the possible benefits of moderate alcohol consumption for the 
risk of heart failure. In addition, it was reported that mild to moderate alcohol consumption 
is associated with a 40–50% lower risk of heart failure than with a previous myocardial infarc-
tion, whereas in the same study, the risk of heart failure without previous myocardial infarc-
tion among people who use heavy drinks was 1.7 times higher than that of abstained. Similar 
results were presented in the study of the health of doctors. The favorable effects of alcohol 
on the risk of developing hypertension, myocardial infarction, and diabetes mellitus have 
also been reported, while alcohol increases the level of high-density lipoprotein cholesterol, 
increases insulin sensitivity, reduces the level of inflammatory markers and clotting factors in 
plasma, and increases the level of adiponectin.
8. Management of cardiovascular risk factors
All current guidelines on the prevention of CVD in clinical practice recommend the assess-
ment of total CVD risk because atherosclerotic CVD is usually the product of a number of 
risk factors. Prevention of CVD in a given person should be adapted to his or her total CVD 
risk: the higher the risk, the more intensive the action should be. The stratification of the com-
munity into different levels of total CVD risk was given in recent guidelines.
8.1. Dyslipidemias
The treatment goals for LDL-C depend on the total CVD risk of the patient and of the baseline 
LDL-C level. In patients at very high CVD risk, an LDL-C goal of <1.8 mmol/L (70 mg/dL), or 
a reduction of at least 50% if the baseline LDL-C level is between 1.8 and 3.5 mmol/L (70 and 
135 mg/dL), is recommended.
In patients at high CVD risk, an LDL-C goal of <2.6 mmol/L (100 mg/dL), or a reduction of 
at least 50% if the baseline LDL-C level is between 2.6 and 5.2 mmol/L (100 and 200 mg/dL), 
is recommended. In subjects at moderate risk, an LDL-C goal of <3.0 mmol/L (115 mg/dL) 
should be considered.
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Statins have proven effective in patients with coronary heart disease; however, their useful-
ness in staging left ventricular dysfunction remains under investigation. The role of statins in 
the prevention of heart failure is shown.
Based on the results of the IMPROVE-IT study, further reduction in LDL-C by the addition of 
ezetimibe should be considered in patients with cardiovascular diseases with LDL-C ≥ 70 mg/
dl (≥1.8 mmol/L), despite the maximum allowable dose of statin. Now a new family of drugs 
that lower lipid levels is available. These inhibitors of subtilisin/kexin type 9 retardate con-
vertase (PCSK9) further reduce LDL-C in addition to what can be achieved with statins. In a 
FOURIER study, inhibition of PCSK9 with evolocumab against statins lowered LDL-C to a 
median of 30 mg/dL (0.78 mmol/L) and reduced cardiovascular events. The use of this drug 
should be considered in patients with a very high risk of cardiovascular disease, in which 
LDL-C remains elevated, despite the fact that it is treated with a maximum dose of statins in 
combination with ezetimibe or in patients with statin intolerance.
8.2. Arterial hypertension
Elevated blood pressure (BP) is one of the most powerful modifiable risk factors for cardio-
vascular disease. The beneficial effects of lowering blood pressure on the reduction of stroke, 
myocardial infarction, heart failure, and death have been shown in numerous RCTs and in 
various meta-analyses. BP reduction can be achieved through lifestyle changes and drug 
therapy [17–19].
Progression progresses from hypertension to structural changes in the ventricles and systolic 
and diastolic ventricular dysfunction. The increase in chronic load, left ventricular mass, and 
stress, accompanied by a deterioration in the properties of diastolic filling, occurs in a chronic 
environment. Disproportionately increased left ventricular mass leads to inadequate micro-
circulation for perfusion of the hypertrophied myocardium, which leads to subendocardial 
hypoperfusion, ischemia. These changes increase the risk of developing coronary thrombosis 
and a heart attack characterized by loss of contractile function, neurohormonal activation, and 
ventricular remodeling, which leads to the development of systolic dysfunction. Anomalies 
in neurohormonal activation and the balance of water and electrolyte also play a role in the 
cascade, which leads to hypertension to heart failure [20–22].
8.3. Dysglycemia and diabetes mellitus
In people with impaired glucose tolerance, the development of type 2 diabetes mellitus (DM) 
can be delayed or prevented. In patients with type 2 diabetes, cardiovascular disease can be 
prevented by good control of risk factors for cardiovascular disease. Intensive management of 
hyperglycemia also reduces the risk of microvascular complications.
Diabetes mellitus is an independent risk factor for heart failure in all age groups. The rela-
tive risk of heart failure in patients with diabetes varies from 1.3 to 2.7, increasing to 4 in 
patients under the age of 65 and 11 in individuals younger than 45 years. Several mechanisms 
have been proposed to explain the increased risk. Combinations associated with heart failure, 
including obesity, hypertension, and coronary artery disease, are common among people 
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with diabetes. Insulin resistance itself can cause disturbances in the cardiac structure and 
function [23–25].
Unfortunately, the prevalence of type 2 DM increases in most parts of the world, mainly 
because of unbalanced diets and lack of physical activity. The diagnosis of DM is also prob-
lematic in a large number of people and even in patients with established CVD. Screening 
should be considered by evaluating HbA1c or fasting blood glucose levels. When there is any 
doubt, you should offer a test for glucose tolerance orally.
For most nonpregnant adults with type 1 or type 2 DM, it is recommended to reduce HbA1c 
< 7.0% (<53 mmol / mol) to reduce the risk of cardiovascular disease and the risk of microvas-
cular complications. When diagnosed or at the beginning of a DM, the target HbA1c ≤ 6.5% 
(≤48 mmol/mol) should be considered in patients who are not brittle and do not have CVD.
Metformin is recommended as first-line therapy if it is tolerated and not contraindicated after 
assessing kidney function. In patients with diabetes and cardiovascular disease, the use of 
sodium glucose-based cotransporter-2 (SGCT2) inhibitors reduced cardiovascular and total 
mortality without significant adverse effects. These drugs should be considered at an early 
stage of treatment of DM in these patients. Optimal management of LDL-C and BP levels is of 
great importance for all patients with DM [3, 24, 25].
8.4. Public awareness of heart failure and compliance
Appropriate care for heart failure and adequate provision of care and research require recog-
nition of its clinical, social, and economic importance not only by health authorities and pro-
viders of health services but also by the general public. Without recognition of the symptoms 
and their severity, people with heart failure will not seek immediate treatment—patients 
often present with a long history of dyspnea. Awareness of the causes of HF can help to 
make appropriate lifestyle changes to reduce the risk. In addition, awareness of the benefits 
of treatment can help compliance and encourage patients to seek appropriate care. However, 
there is a lack of information about public awareness of HF. Studies have shown a relatively 
low understanding and treatment of heart failure by general practitioners. If doctors are not 
aware of the importance of HF, it is unlikely that the general public will have a good under-
standing [26–28].
A large number of premature deaths are due to ignorance of the causes and symptoms of 
heart failure. There is an urgent need for public information programs that determine heart 
failure in a simple and accessible language, explain how to recognize symptoms, and stress 
the need for emergency medical care. Other important messages are that most types of heart 
failure can be prevented and a healthy lifestyle can reduce the risk. Policymakers should sup-
port the development and implementation of public awareness programs targeted at these 
messages. The public understanding of the symptoms of heart failure is dangerously low.
Cost-effective information, education, and support programs to reduce the risk of heart fail-
ure should be at the forefront of public health guidelines. Lifestyle events can have a signifi-
cant impact on the health of the world, because obesity, diabetes, cigarette smoking, and high 
blood pressure significantly increase the likelihood of heart failure. Renewing commitment 
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to public education, the importance of healthy nutrition and weight, regular exercise, and 
prevention of smoking should be a priority for policymakers [29, 30].
In low- and middle-income countries, lifestyle-based measures to prevent heart failure were 
calculated as more cost-effective than pharmaceutical interventions. The acute need to take 
risks into life throughout the world is recognized by the United Nations, including in regions 
such as sub-Saharan Africa, where noncommunicable diseases associated with western 
lifestyles are not yet the leading causes of death or disease. Given the increasing number 
of patients with heart failure in economically developing regions, governments should be 
encouraged to combine lifestyle-based preventive measures with their programs to combat 
hunger and the epidemic. One could consider the issue of regulating aggressive marketing 
of high-calorie foods by large global corporate enterprises, especially schoolchildren and 
adolescents [31–33].
Compliance with the recommendations of clinical practice is often associated with improved 
outcomes for patients with heart failure. However, in many countries there are significant 
differences in how closely hospitals follow the recommendations of national recommenda-
tions for heart failure. In response, policymakers must protect the fairness of care for all 
patients. First, it is important to promote heart failure training programs that raise aware-
ness of the guidelines among all relevant health professionals. Secondly, better care should 
be encouraged, using performance indicators and incentives appropriate to local conditions. 
Funding is needed to research evidence-based health-care performance indicators that reflect 
improvements in clinical outcomes for patients with heart failure. By improving health care, 
policymakers can provide a health system that provides timely access to the diagnosis and 
treatment of heart failure and then a consistent transition to long-term management.
Diagnosis of heart failure can be difficult, even for skilled professionals. Not all patients with 
heart failure have typical symptoms, and the same symptoms can be experienced by patients 
who do not have heart failure. For an accurate diagnosis, a number of diagnostic tools and 
information are required in combination with clinical judgment and expert knowledge.
Many patients initially do not see an expert in heart failure due to the fact that they are part of 
the health-care system. Those with severe symptoms, such as dyspnea at rest, are most often 
evaluated by paramedics or emergency doctors in the hospital, whereas those with less obvi-
ous life-threatening symptoms are more likely to go to their family doctor or outpatient clinic. 
Educational programs are needed to raise awareness about clinical practice recommendations 
among health professionals from a wide range of specialties that may be the first to encounter 
patients with undiagnosed heart failure.
Recommendations for the use of drugs for the treatment of heart failure are based on clinical 
trials conducted mainly in Europe and the United States. In other parts of the world, the under-
lying causes of heart failure are different, and it is not safe to assume that drugs will be equally 
effective in all patient groups. A further clinical study to investigate the efficacy of treating 
heart failure in different patient groups around the world should be maintained [32–34].
The world survey showed the need to improve patients’ self-care. Most patients reported 
taking medication as prescribed, but few reported having control of their weight or regu-
lar training. Educational programs are a priority, but they need to be developed carefully, 
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because it is reported that patients with a deeper knowledge of heart failure are more likely 
to delay treatment. This may reflect false optimism and a lack of understanding that control-
ling the symptoms of heart failure does not slow the progression of the disease. The learning 
environment should also be carefully considered. Short video clips, text messages, and social 
networks can be used to deliver simple but accurate messages. Currently, according to esti-
mates, 6 billion people own a mobile phone; technology can be an important way to reach 
remote and socially economically disadvantaged [27–31].
Teaching people how to support a partner, family member, or friend with heart failure is also an 
important part of encouraging self-help. Patients are more likely to engage in useful self-help if 
they have someone who will help them than if they were socially isolated. This emphasizes the 
need to improve support for communities of socioeconomically disadvantaged patients and 
those who live alone. Policymakers should provide resources to educate and support people 
with heart failure and their caregivers, allowing them to actively engage in long-term care.
9. Conclusion
Prevention of disease and death due to heart failure should be a priority in the field of health. 
Despite the increasing number of people living and dying of heart failure, awareness of this 
disease is low among the public, politicians, and even some health professionals. Despite 
the lack of treatment for heart failure, many cases can be prevented, and most patients can 
effectively be treated to improve quality of life and survival. Policymakers are responsible 
for ensuring that as many people as possible can take advantage of affordable prevention, 
diagnosis, treatment, and long-term treatment of heart failure. At the same time, research 
should be supported in areas where immediate unmet needs exist.
All current recommendations for the prevention of cardiovascular disease in clinical practice 
recommend an estimate of the overall risk of cardiovascular disease, since atherosclerotic car-
diovascular risk is usually the result of a number of risk factors. Prevention of cardiovascular 
disease in this person should be adapted to his or her overall risk of cardiovascular disease: 
the higher the risk, the more intense the action should be.
The positive impact of specialized management programs on survival suggests that these fac-
tors also lead to a significant number of preventable deaths. Many of the factors listed above 
are often considered in “normal conditions” of clinical trials with increased monitoring and 
individualized observation. It is therefore not surprising that patients in clinical trials usually 
have lower than expected morbidity and mortality rates.
Any program aimed at improving long-term management must recognize that patients with 
heart failure play a key role in their own care. Self-service includes maintenance, monitoring, 
and management. Maintenance involves taking medication as prescribed, regular meals, and 
a healthy diet. Monitoring involves monitoring of symptoms and weight (which can serve 
as a warning sign of increasing fluid accumulation). Management involves responding to 
changes in symptoms by adjusting the doses of certain drugs if they are prescribed for “use 
as needed” (e.g., drugs that increase urine production to reduce fluid accumulation) or by 
seeking medical help if symptoms worsen.
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